People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BioCritica, Inc. | — | Pharmaceuticals | Series B | $25.0M | $850.1M | 2011 |
ARGERIS N. KARABELAS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ARGERIS N. KARABELAS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ronald J. Wooten | 1 | 2 |
| Lorenzo N. Pellegrini | 1 | 2 |
| David A. Broecker | 1 | 2 |
| MIKE F. JOHNSON | 1 | 1 |
| MICHAEL D. PAGNOTTA | 1 | 1 |
| MARK D. WILLIAMS | 1 | 1 |
| DARREN J. CARROLL | 1 | 1 |
| MICHAEL J. BOLOGNA | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.